GlassScriptPhysician profile
Lance C Foster
NPI 1891740502
$3,694.94
in general payments reported to CMS, 2019-2025
23 companies · $945 in 2025
The $945 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $185 · 2021: $204 · 2022: $262 · 2023: $464 · 2024: $879 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,288.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $424.17 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $422.39 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $317.98 | 2019-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $311.41 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $242.79 | 2023-2025 | Auvelity |
| Corium, LLC | $235.89 | 2022-2025 | Azstarys |
| Abbvie INC. | $220.59 | 2021-2025 | |
| Lundbeck LLC | $210.91 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $180.27 | 2019-2025 | Ingrezza |
| Allergan, INC. | $172.06 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $151.14 | 2019-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $119.82 | 2022-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $105.49 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $98.99 | 2019-2021 | |
| Shire North American Group INC | $93.24 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $91.55 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $84.21 | 2022-2024 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $64.33 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $47.14 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $40.30 | 2020-2022 | |
| Bausch Health US, LLC | $24.57 | 2024 | Aplenzin |
| Vertical Pharmaceuticals, LLC | $19.84 | 2019 | |
| Eisai INC. | $15.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.